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Abstract: The aim of the present study was to assess the short-term effects of Thymoquinone (TQ) on
oxidative stress, glycaemic control, and renal functions in diabetic rats. DM was induced in groups II
and III with a single dose of streptozotocin (STZ), while group I received no medication (control).
The rats in groups I and II were then given distilled water, while the rats in group III were given
TQ at a dose of 50 mg/kg body weight/day for 4 weeks. Lipid peroxidase, nitric oxide (NO), total
antioxidant capacity (TAC), glycated haemoglobin (HbA1c), lipid profiles, and renal function were
assessed. Moreover, the renal tissues were used for histopathological examination. STZ increased the
levels of HbA1c, lipid peroxidase, NO, and creatinine in STZ-induced diabetic rats in comparison to
control rats. TAC was lower in STZ-induced diabetic rats than in the control group. Furthermore, rats
treated with TQ exhibited significantly lower levels of HbA1c, lipid peroxidase, and NO than did
untreated diabetic rats. TAC was higher in diabetic rats treated with TQ than in untreated diabetic
rats. The histopathological results showed that treatment with TQ greatly attenuated the effect of
STZ-induced diabetic nephropathy. TQ effectively adjusts glycaemic control and reduces oxidative
stress in STZ-induced diabetic rats without significant damaging effects on the renal function.
Keywords: diabetes mellitus; glycaemic control; lipid profiles; oxidative stress; renal function;
thymoquinone
1. Introduction
Diabetes mellitus (DM), a chronic metabolic disorder that is prevalent in humans,
is associated with abnormally high levels of glucose in the blood. Elevated glucose lev-
els increase oxidative stress [1] by stimulating various mitochondrial enzymes, which
results in the overproduction of reactive oxygen species (ROS) [2] and has detrimental
effects on many organs [3]. Mullarkey et al. [4] reported multifactorial aetiologies of the
augmented levels of oxidative stress associated with DM. Recent studies have shown
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that β-cell dysfunction in diabetic patients is mostly the result of enhanced oxidative
stress [1,5]. Other conditions associated with DM are hypertriglyceridemia, low levels of
high-density lipoprotein (HDL), and high levels of low-density lipoprotein (LDL) [6], all of
which contribute significantly to the development of atherosclerosis [7]. When exploring
the efficacy of anti-diabetic drugs, having antioxidant effects [8,9], efficacy in correcting
dyslipidaemia [10] and hyperglycaemia [11], as well as safety, are crucial.
Current diabetes treatments include insulin and a number of oral antidiabetic drugs
with severe adverse effects; thus, it remains a challenge to manage diabetes without any side
effects. The search for more efficient and safe hypoglycaemic agents has therefore remained
an important research area [12]. Thymoquinone (TQ), the main volatile constituent of oil
from Nigella sativa seeds, has been shown to have a broad therapeutic spectrum [13–16],
and studies on the potential effects of TQ on oxidative stress, β-cell damage, and dia-
betic nephropathy are promising [17,18]. TQ exhibits protective effects against diabetes,
inflammation, and oxidative stress. The antioxidant and anti-inflammatory activities of TQ
may cause its clinical effect against various diseases. It penetrates physiological barriers
and accesses subcellular compartments and exhibits the radical scavenging effects. It also
reacts with glutathione (GSH), NADH, and NADPH to form glutathionyl-dihydro-TQ (re-
duced species) and combats free radicals [19]. TQ can be effective in persons with glucose
intolerance as it helps to reduce appetite, glucose absorption, hepatic gluconeogenesis,
blood glucose, cholesterol, triglycerides, and body weight. It simulates glucose-induced
insulin secretions from pancreatic beta cells and improves glucose tolerance as effectively
as metformin [20]. Megantara et al. [21] confirmed the antidiabetic activity of TQ against
pioglitazone. Al-Ali et al. [22] established the safety of TQ administered orally to experi-
mental animals through determining the lethal dose (LD50) of TQ both in mice and rats.
Asgary et al. [23] reported that TQ is safe and well-tolerated with no severe side effects. If
short-term therapy is the best treatment method, then this could result in a reduction of
waitlists and thus a better entrance to evidence-based care [24].
The aim of the present study was to evaluate the short-term effects of TQ on oxidative
stress, glycaemic control, lipid profile, and renal function.
2. Material and Methods
2.1. Materials
Streptozotocin (STZ), TQ, and total glycated haemoglobin kits were purchased from
Sigma–Aldrich (St. Louis, MO, USA). Lipid peroxidation (LPO) assay kit, total serum
nitrate/nitrite (NO) kit, total antioxidant capacity (TAC) kit, and serum creatinine and
urea concentrations kits were purchased from Biodiagnostic (Cat. Tahrir, Cairo, Egypt).
Triglycerides assay kit, total cholesterol assay kit, and HDL and LDL precipitating reagent
kits were purchased from United Diagnostics industry (UDI, Makka, KSA). All chemicals
used were of analytical grade and were used as received without any further purification.
All solutions were prepared with Millipore water.
2.2. Ethics
This study was approved by the Subcommittee of Health Research Ethics, Deanship
of Scientific Research, Qassim University (Approval No: 18-01-09), in accordance with the
National Research Council (US) Guide for the Care and Use of Laboratory Animals [25].
2.3. Animals
The present study used 18 male Sprague-Dawley rats, weighing 200–250 g. The
rats were maintained at a temperature of 24–25 ◦C and a humidity of 50–80% under a
12:12 h light:dark cycle with free access to standard rat pellets and water throughout the
experiments. The animals were treated according to the principles outlined in the NIH
Guide for the Care and Use of Laboratory Animals [26]. Rats were obtained from the
animal house of King Saud University/Kingdom of Saudi Arabia (KSA), acclimatised to
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the laboratory conditions at 25 ◦C for one week and fed a standard diet with water ad
libitum at College of applied medical sciences (CAMS)/ Qassim University/KSA.
2.4. Induction of Diabetes
The study included three equal groups of rats (N = 6 rats for each group). DM was
induced in groups II and III with a single dose (65 mg/kg body weight) of STZ that was
freshly dissolved in 5 mM citrate buffer, pH 4.5 [27]. Control animals (group I) were injected
with an equal volume (1 mL) of the buffer solution alone. Fasting blood glucose levels
(BGLs) were assessed with a glucometer (Accu-Chek Active, Roche Diagnostics, Germany)
two days after the injection of STZ. Rats were considered diabetic if the BGL was greater
than 200 mg/dL [28]. Subsequently, all animals were maintained for 4 weeks on ad libitum
food and water with checking of fasting blood glucose, average body weight, and food and
water ingestion before the beginning of treatment with TQ [19].
2.5. Administration of the Experimental Drug
The control rats in group I were healthy rats. The rats in group II (untreated diabetic
group) received no medications. Both groups I and II were given 1 mL of distilled water
per 100 g of body weight/day by oral gavage for 4 weeks. The rats in group III were given
TQ, which was initially dissolved by adding dimethyl sulfoxide (DMSO), followed by
normal saline (for a final DMSO concentration of less than 0.5%). The resulting TQ solution
was administered at a dose of 50 mg/kg of body weight once daily using gastric gavage
for up to 4 weeks [19].
2.5.1. Sample Collection
Rats were anaesthetised with ether and sacrificed at the end of the experimental
period (4 weeks). Blood samples were collected from the medial canthus of the eye via
heart puncture into sterilised tubes for serum separation, while whole blood was used to
assess total glycated haemoglobin (HbA1c) [29].
2.6. Total Glycated Haemoglobin
Total glycated haemoglobin was assessed with a total glycated haemoglobin kit (Sigma–
Aldrich, St. Louis, MO, USA) according to standard techniques adopted by Bunn et al. [30].
2.7. Oxidative Stress Assays
2.7.1. Lipid Peroxidation (LPO)
The state of LPO was assessed colorimetrically with a lipid peroxide kit (Biodiagnostic,
CAT. NO MD 2529, Egypt) according to Ohkawa et al. [31]. Using this colorimetric method,
thiobarbituric acid (TBA) reacts with malondialdehyde (MDA) in an acidic medium at a
temperature of 95 ◦C for 30 min to form reactive TBA products. The absorbance of the
resulting (pink) product was measured at 534 nm with a lipid peroxide kit (Biodiagnostic,
CAT. NO MD 2529). The values are expressed in nM.
2.7.2. Total Antioxidant Capacity (TAC)
TAC was measured colorimetrically with a TAC kit (Biodiagnostic, CAT. NO TA2513,
Egypt), according to Koracevic et al. [32]. Using this method, antioxidant capacity was
analysed via a reaction between the antioxidants in the sample and a known amount of
exogenous hydrogen peroxide (H2O2). Antioxidants in the sample eliminate a portion
of the hydrogen peroxide, and the residual H2O2 is measured colorimetrically via an
enzymatic reaction that converts 3,5-dichloro-2-hydroxybenzenesulfonate to a coloured
product, which is subsequently measured at 505 nm. The values are expressed in mM/L.
2.7.3. Determination of Total Serum Nitric Oxide (NO)
The levels of NO were represented by total nitrite concentrations using a colorimetric
method called the Griess reaction. The colour—developed by reacting with the Griess
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reagent (1% sulphanilamide/0.1% naphthylethylenediamine dihydrochloride, w/v in 2.5%
H3PO4)—was recorded at 550 nm against a reagent blank using 10–100 µM sodium nitrite
as a standard [33]. The values are expressed in nmol/mL.
2.8. Assessment of Serum Creatinine and Serum Urea
2.8.1. Serum Creatinine
Serum creatinine was measured colorimetrically with a creatinine kit (Crescent Diag-
nostics, CAT. NO CS604, KAS) using the kinetic Jaffe reaction (i.e., without deproteiniza-
tion) [34]. In the Jaffe reaction, creatinine reacts with an alkaline precipitate to produce
a reddish orange colour, the intensity of which is directly proportional to the creatinine
concentration at 490 nm. The values are expressed in mg/dL.
2.8.2. Serum Urea
Serum urea was measured using a urea kit (Crescent Diagnostics, CAT. NO CS612,
KSA) using an enzymatic, colorimetric endpoint (i.e., the Berthelot method) [35]. In this
reaction, urease catalyses the conversion of urea to ammonia. In a modified Berthelot
reaction, ammonia ions react with a mixture of salicylate, hypochlorite, and nitroprusside
to yield a blue–green dye (indophenol). The intensity of this dye, which is measured




A triglycerides assay kit (CAT. NO EL59L-1000, KSA) was used to measure serum
triglycerides using the enzymatic-colorimetric glyceryl phosphate oxidase method [36].
The values are expressed in mg/dL.
2.9.2. Total Cholesterol
A total cholesterol assay kit from UDI (CAT. NO EL24-1200, KSA) was used to measure
total cholesterol via an enzymatic, liquid, colorimetric test called the cholesterol oxidase
phenol 4-aminoantipyrine peroxidase (CHOD/PAP) method [37]. The values are expressed
in mg/dL.
2.9.3. HDL Cholesterol
A kit from UDI (CAT. NO EL41-360, KSA) was used to measure HDL via the enzymatic-
colorimetric phosphotungstate method [38]. Using this method, LDLs and very low-density
lipoproteins (VLDLs) are precipitated out when the serum reacts with the precipitating
reagent, while the HDL fraction remains in the supernatant. The supernatant is then used
as a sample in the cholesterol assay. The values are expressed in mg/dL.
2.9.4. LDL Cholesterol
LDL was measured indirectly based on the levels of total cholesterol, HDL, and
triglycerides using the Friedewald formula [39]:
LDL = Total cholesterol − HDL − (Triglycerides/5)
The values are expressed in mg/dL.
2.10. Histopathological Evaluation of the Kidneys
The kidneys from each animal were sliced and fixed in 10% buffered neutral formalin.
The formalin-fixed tissues were dehydrated and infiltrated using an automated tissue
processor (Leica TP1020) and embedded in paraffin wax. Serial 5 µm thick sections were
prepared using a microtome (Leica RM2245) and stained using haematoxylin and eosin. The
measurements of the diameter of the renal corpuscle (RC), glomeruli (GM), and Bowman’s
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space (BS) were made using a light microscope (Olympus BX41), a digital microscope
camera (5MP binocular microscope, electronic eyepiece USB video CMOS camera, and
TopView Image Analyzer). Six GM were measured for each animal, and an average was
taken for each individual.
Arteriolosclerosis was graded as described by Sommers et al. [40], where grade 0 indi-
cates unaltered arterioles, grade 1 describes minor localised thickening, grade 2 represents
a thickened wall equal to the diameter of the lumen, and grade 3 describes arterioles with
wall thickness that exceeded the diameter of the lumen. Hyaline droplets were assessed as
number per 50 high-power fields (HPFs). All Hematoxylin -Eosin (HE)-stained sections
from both immersion and perfusion samples were examined histopathologically, with
special regard to hyaline droplets and eosinophilic bodies.
2.11. Statistics
Statistical analyses were performed using SPSS (Version 16; IBM Corp., Armonk, NY,
USA). Data are expressed as the mean (M) ± standard deviation (SD). Normal distribution
was assessed using the Shapiro–Wilk test. One-way Analysis of variance (ANOVA) and
Least Significant Difference (LSD) post hoc tests were used to assess significant differences
between the means of the measured parameters (i.e., oxidative stress, HbA1c, serum
lipids, urea, and creatinine) in the studied groups. A p-value of <0.05 was considered to be
statistically significant.
3. Results
By measuring HbA1c, the overall picture of average blood sugar levels can be de-
termined over a period of weeks/months. The results showed that the levels of HbA1c
were significantly higher in untreated diabetic rats (9.0% ± 0.7%) than in control rats
(4.5% ± 0.5%, p < 0.001), indicating that DM was successfully induced by STZ in Sprague-
Dawley rats at a dose of 65 mg/kg of body weight (Table 1).
Diabetic rats exhibited higher levels of lipid peroxidase (17.5 ± 1.03 nM) and NO
(18.4 ± 5.1 nM) than control rats (9.5 ± 2.2 nM and 9.3 ± 5.1 nM respectively, p ≤ 0.01),
indicating that inducing DM in Sprague-Dawley rats resulted in an increase in oxidative
capacity (Table 1).
TAC was significantly lower in untreated diabetic rats (0.2 ± 0.04 mM/L) than in the
control group (0.8 ± 0.2 mM, p < 0.001, Table 1).
There were no significant differences between the urea concentration and lipid profiles
of untreated diabetic and control rats. In contrast, creatinine levels were significantly higher
in untreated diabetic rats (1.2 ± 0.2 mg/dL) than in control rats (0.9 ± 0.1 mg/dL) (Table 1).
Treating diabetic rats with TQ (at a dose of 50 mg/kg body weight) significantly
decreased the levels of HbA1c (6.7% ± 1.0%), lipid peroxidase (10.6 ± 2.3 nM), and NO
(12.5 ± 2.98 nM) in comparison to untreated diabetic rats (9.0% ± 0.7%, 17.5 ± 1.02,
and 18.4 ± 5.1 respectively, p < 0.05, Table 1). In addition, the finding that TAC was
significantly higher in diabetic rats treated with TQ (0.6 ± 0.2 mM) than in untreated
diabetic rats (0.2 ± 0.04 mM, p = 0.001) indicates that TQ enhances antioxidant defence
mechanisms. Interestingly, a comparison of parameters related to oxidative stress levels of
lipid peroxidase and NO between diabetic rats treated with TQ and control rats revealed
that there were no statistically significant differences between the two groups (p > 0.05).
Furthermore, the total cholesterol and urea levels of untreated diabetic rats and diabetic
rats treated with TQ were nearly similar to those of the control group (Table 1).
Kidney sections stained with HE of the control rats (group I) showed normal GM
(Figure 1A). After 4 weeks of STZ treatment, sections showed an increase in the diameter of
RC, GM, and BS in the untreated diabetic rats (group II); however, GM did not achieve a sta-
tistical difference (Figure 1B and Table 2). There were reversible changes after the treatment
with TQ (group III), which showed a significant reduction in RC, GM, and BS (Figure 1C).
The diameters of RC, GM, and BS of TQ-treated rats decreased and became comparable
with the control group (Table 2). Figure 2 and Table 2 show the effects of STZ and TQ
Molecules 2021, 26, 2348 6 of 13
on tubulointerstitial morphology (upper image) and arteriolosclerosis (lower images).
Control group shows normal tubulointerstitial morphology and grade 0 arteriolosclerosis
(Figure 1A). The inflammatory cell infiltration and hyaline droplets in untreated (group II)
and TQ-treated (group III) diabetic rats are shown in Figure 1B and C, respectively. The
vertical black arrow indicates hyaline droplets, inflammatory cells are enclosed in a black
circle, and arterioles are indicated by horizontal black arrows. Arteriolosclerosis was ob-
served in the untreated diabetic group in most of the examined fields, where wall diameter
exceeded that of the lumen in nearly all sclerotic arterioles. However, the degree of sclerosis
was markedly reduced in TQ-treated diabetic rats. The renal tubules were dilated and
hypertrophied in the untreated diabetic group in comparison to the TQ-treated diabetic
group (Table 2, Figures 1 and 2).





TQ Treated Diabetic Group
M ± SD F p
Glycaemic Control
-HbA1c 4.5 ± 0.5 9.0 ± 0.7 * 6.7 ± 1.0 *# 14.68 <0.001
Oxidative Stress
-Lipid Peroxidase (nM) 9.5 ± 2.2 17.5 ± 1.03 * 10.6 ± 2.3 # 15.29 <0.001
-NO (nmol/mL) 9.3 ± 5.1 18.4 ± 5.1 * 12.5 ± 2.98 # 7.16 0.001
-TAC (mM/L) 0.8 ± 0.2 0.2 ± 0.04 * 0.6 ± 0.2 *# 26.14 <0.001
Lipid Profile
-Total Cholesterol (mg/dL) 112.2 ± 3.2 117.5 ± 13.3 113.3 ± 6.7 0.97 0.441
-Triglycerides (mg/dL) 124.6 ± 2.1 108.8 ± 17.7 113.7 ± 4.4 * 3.40 0.024
-HDL (mg/dL) 46.9 ± 11.1 40.4 ± 6.4 32.3 ± 8.9 * 4.44 0.008
-LDL (mg/dL) 40.4 ± 11.3 55.3 ± 13.5 * 58.2 ± 4.8 * 10.17 <0.001
Renal Function
-Urea (mg/dL) 20.2 ± 2.0 23.7 ± 6.9 27.7 ± 3.8 * 0.95 0.454
-Creatinine (mg/dL) 0.9 ± 0.1 1.2 ± 0.2 1.1 ± 0.2 2.66 0.056
Abbreviations: NO = nitric oxide, TAC = total antioxidant capacity, HbA1c = glycated haemoglobin, HDL = high-density lipoprotein,
LDL = low-density lipoprotein. F = the ratio of the between group variance to the within group variance. p = p-value, * significantly
different compared with group I, # significantly different compared with group II. M ± SD = mean ± standard deviation.
Table 2. Diameters of the glomerulus, Bowman’s space, and the renal corpuscle, and an assessment of arteriolosclerosis,





TQ Treated Diabetic Group
M ± SD F p
Diameter of RC (µm) 193.48 ± 20.12 228.08 ± 23.42 * 216.95 ± 11.56 3.44 0.077
Diameter GM (µm) 158.10 ± 19.98 170.00 ± 22.81 184.40 ± 6.92 2.15 0.172
Diameter of BS (µm) 22.10 ± 4.29 30.93 ± 4.96 * 16.23 ± 1.71 # 14.33 0.002
Arteriolosclerosis Grade 0 Grade 3 Grade 1
Inflammatory cell infiltration Insignificant Mild Mild
Hyaline droplets Insignificant 30% 20%
F = the ratio of the between group variance to the within group variance. p = p-value, * significantly different compared with group I,
# significantly different compared with group II. M ± SD = mean ± standard deviation.
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Figure 1. Effects of streptozotocin (STZ) and TQ on glomerular morphology. (A) Control group (Group I), (B) untreated
diabetic group (Group II), and (C) TQ-treated diabetic group (Group III). The black arrow indicates an increase in Bowman’s
space. H&E staining, magnification = 400 X.
Figure 2. Effects of streptozotocin and TQ on tubulointerstitial morphology (upper images) and on arteriolosclerosis (lower
images). (A) Control group (Group I), (B) untreated diabetic group (Group II), and (C) TQ-treated diabetic group (Group III).
The vertical black arrow indicates hyaline droplets, inflammatory cells are enclosed in a black circle, and arterioles are
indicated by horizontal black arrows. H&E stain; magnification = 400 X in the upper images and 100 X in the lower images.
4. Discussion
The present study sought to elucidate the short-term effects of TQ as a safe natural
product for treatment and controlling oxidative stress, glycaemic control, lipid profile,
and renal functions in diabetic rats. The present study revealed several findings. First,
we demonstrated that inducing DM in Sprague-Dawley rats significantly disturbs the
normal redox state, as was indicated by altered levels of lipid peroxidase, NO, and TAC in
untreated diabetic rats relative to control rats. Similar to the findings of Siboto et al. [41]
and Sassy-Prigent et al. [42], histopathology in the present study revealed that injecting
rats with STZ resulted in glomerular hypertrophy, which could be largely attributed to
mesangial expansion and the thickening of the glomerular basement membrane.
Another important finding is that treating diabetic rates with TQ successfully im-
proved glycaemic control and attenuated oxidative stress. Interestingly, we observed
that the levels of lipid peroxidase, NO, and TAC were similar or better in diabetic rats
treated with TQ compared to control rats, indicating that TQ exerts a positive effect on
oxidative stress. Additionally, treatment with TQ decreased the diameter of the RC in
comparison to that of untreated diabetic rats, while the diameter of BS in diabetic rats
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treated with TQ decreased even beyond that of control rats. This can be attributed to the
capsular thinning and glomerulus preservation observed when comparing the glomerulus
diameters in treated and untreated diabetic groups. Ozdemir et al. [43] reported a direct
relationship between an increase in the area of BS and blood glucose levels in STZ-induced
diabetic nephropathy. The present study demonstrates that treatment with TQ reduces
arteriosclerotic changes in the kidney sections taken from treated diabetic rats. Arteri-
olosclerosis is widely reported in cases of diabetic nephropathy and represents one of the
underlying pathophysiological mechanisms of this disease, in addition to oxidative stress
and associated inflammation [44].
A study performed by Seyer-Hansen et al. [45] on renal hypertrophy in rats with STZ-
induced DM found that the length of renal tubules increased to more than 100 m/kidney
and that the diameter of the renal tubular lumen significantly increased 47 days after the
onset of DM. Although hyaline droplets are not specific to DM, their presence is largely
related to the severity of the disease, as they are directly correlated with the degree of
proteinuria [46]. In the present study, treating diabetic rats with TQ reduced the percentage
of hyaline droplets by 10%.
The present study also revealed that inducing DM in Sprague-Dawley rats and subse-
quently treating with TQ did not substantially affect rat lipid profiles over the experimental
period. STZ is commonly used to induce DM in rodents on an experimental basis, likely
owing to its harmful effects on β-cells in the pancreas [47]. The cytotoxic action of STZ on
pancreatic β-cells is likely mediated by enhanced intracellular methylation reactions, DNA
strand breaks, and ROS production [48]. However, the molecular mechanisms underlying
STZ-induced cell toxicity are still unclear. A recent study conducted by Raza and John [49]
investigated STZ-induced cytotoxicity in human hepatoma cells by treating hepatoma
cells with different doses of STZ for various time intervals and observing the cytotoxic
effects via alterations in redox balance. According to their results, STZ increased levels of
oxidative stress, which was evident by the elevated levels of LPO and altered antioxidant
capacity. These findings are further supported by the results of the present study, which
also observed an increase in the levels of LPO and NO, but a decrease in TAC following
the administration of STZ to Sprague-Dawley rats.
It is evident that the disruption of redox balance following the administration of STZ
to the Sprague-Dawley rats in the present study was successful in establishing DM and
compromised renal function. Altered renal function, as indicated by the significantly higher
creatinine levels in untreated diabetic rats in comparison to control rats, is likely the result
of a disruption to redox balance in the renal cortex [48] and/or increased renal vascular
resistance [50,51]. In the early 2000s, Jacheć et al. [52] investigated disturbances in redox
balance in the renal cortex of rats over the course of experimental diabetes. The results of
that study were comparable to the findings of the current study in that they observed that
plasma creatinine was significantly elevated following the induction of diabetes by STZ.
It has been previously shown that STZ-induced DM is likely to induce an athero-
genic pattern of dyslipidaemia [52,53]. Hypercholesterolemia in STZ-induced diabetic rats
usually results from enhanced intestinal absorption and an increase in cholesterol synthe-
sis [54]. In the current study, changes in the levels of total cholesterol, LDL, and HDL were
characteristic of an atherogenic pattern of dyslipidaemia; however, most of these lipids
were not significantly different between untreated diabetic rats and the control group. In
addition, the present study found that HbA1c levels were significantly lower following
the treatment of STZ-induced diabetic rats with TQ, while the levels of lipid peroxidase,
NO, and TAC were better than untreated diabetic rats. These findings provide further
confirmation of the potential beneficial effects of TQ on glycaemic control [55,56] and
oxidative stress [57,58], despite the fact that most previous studies were mainly conducted
using the plant N. sativa rather than the active ingredient TQ.
Fararh et al. [11] examined the effect of TQ on glycaemic control and energy metabolism-
related enzymes in the leukocytes of STZ-induced diabetic rats and reported significantly
lower plasma glucose levels following treatment with TQ. The suggested mechanisms
Molecules 2021, 26, 2348 9 of 13
of action of TQ in lowering glucose are thought to be increased insulin levels and the
enhanced activities of some cytosolic and mitochondrial enzymes. These findings are fur-
ther supported by Pari and Sankaranarayanan et al. [59], who showed that TQ therapy
was associated with beneficial changes in hepatic enzyme activities and subsequently in
hypoglycaemic effects. The lower levels of HbA1c in diabetic rats treated with TQ may also
be enhanced by the increased turnover of red blood cells (RBCs) [60–62]. This is because
the decrease in HbA1c from the rapid turnover of RBCs is likely to be lower than that of
HbA1c formation owing to the improved glycaemic control induced by TQ.
Although previous studies have demonstrated the hypolipidemic effect of TQ [59], the
present study and several other previous studies failed to prove this effect. Interestingly,
an older study by Bamosa et al. [63] conducted in healthy humans showed that while the
ingestion of powdered N. sativa for two weeks was associated with a significant decrease in
plasma cholesterol level in the first week, this parameter paradoxically increased to original
levels by the end of the second week. Although the findings of Bamosa et al. are difficult
to interpret, they are in agreement with the present results, which failed to demonstrate
a significant effect of TQ treatment on the lipid profile of diabetic rats after four weeks.
Our findings with regard to the effect of TQ on the lipid profile are supported not only by
Bamosa et al., but also by a randomised, double-blind trial conducted by Qidwai et al. [64],
which assessed the effectiveness of powdered N. sativa in lowering the serum lipid profile.
The results of the study by Qidwai et al. failed to demonstrate a statistically significant
favourable impact of N. sativa on the levels of triglycerides, total cholesterol, HDLs, or
LDLs. Based on previous reports and the current study, it may be hypothesised that TQ
treatment decreases the lipid profile for only a short duration but has no long-term effects,
likely owing to desensitisation mechanisms. Further studies are needed to compare the
short- and long-term effects of TQ treatment on serum lipid profiles.
A potential limitation of the present study is that serum insulin and C-peptide levels
were not assessed. Further studies that correlate the attenuation in oxidative stress with
improved levels of insulin or C-peptide following treatment with TQ would support the
present study to provide a more complete picture of the effectiveness of this promising
treatment. Another limitation of the present study is that the pancreas, liver, kidney, and
respiratory system were not examined histologically to exclude any possible toxic effects
of TQ treatment on these organs. Noteworthy, the rats treated with TQ were exposed
to DMSO, but not the other studied groups. Theoretically speaking, DSMO may act as a
confounding factor for the observed effects of TQ in the present study. Investigators in
the field are requested to consider this potential limitation in future studies. Addition of a
fourth vehicle (DSMO) group of rates to the study protocol will help to explore the possible
effects of DSMO on the studied variables.
In conclusion, the results of the present study demonstrate the potential therapeutic
effects of TQ in lowering BGL and attenuating oxidative stress. Moreover, treatment with
TQ at a dose of 50 mg/kg body weight exerted no detectable detrimental effects on renal
function in rats; however, further studies are needed to adjust the optimal dose for future
human studies. Although TQ exhibited a protective effect on glomeruli by reducing BS, and
opposed the diabetic effect of STZ, the underlying mechanism for the observed increase
in the diameter of the GM in diabetic rats treated with TQ is unclear. While phenomena
such as mesangial proliferation, capillary proliferation, or oedema could be the leading
cause of this effect, further investigation will be necessary to elucidate the molecular
mechanisms at work.
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